Center Laboratories, Inc. is a professional investment holding company that transitioned from its origins in the pharmaceutical industry in 1959. The firm provides capital support, corporate restructuring, strategic planning, talent training, technology incubation, and market expansion services to portfolio companies. Its investment portfolio spans the biotechnology and healthcare sectors, including infant formula and nutritional products, clinical-stage drug development for neurological and oncological conditions, and contract development and manufacturing organizations (CDMOs) specializing in biologics, antibody-drug conjugates, peptides, and oligonucleotides. The company also holds stakes in advanced orthopedic medical devices, functional probiotics, and hydrogen energy technology. Notable portfolio entities include Ausnutria, Lumosa Therapeutics, Yisheng Biotech, Fenghua Biotech, Yongxin Biotech, Dongyao Pharmaceutical, Jianyi Biotech, Shanghai Baoji Pharmaceutical, and Bosheng. The group also supports gene therapy ventures such as GenEditBio and hydrogen energy projects like Youmu Technology.

Summarised from the company's own disclosures

Industry Asset Management Homepage centerlab.com.tw
Sector Financial Services IR page centerlab.com.tw/investor
Tags
biotechnology, pharmaceuticals, cdmo, infant formula, gene therapy, hydrogen energy, medical devices, probiotics, oncology, neurology, Ausnutria, Jia Bei Ai Te, Lumosa Therapeutics, Yisheng Biotech, Fenghua Biotech, Yongxin Biotech, Dongyao Pharmaceutical, Jianyi Biotech, Shanghai Baoji Pharmaceutical, Bosheng, Ai Xi Kang, GenEditBio, Youmu Technology
Press page —

Metrics

Valuation  
Market cap NT$ 20.481B
Market cap (USD) $ 621.633M
P/E -14.09
PEG —
P/BV 1.21
P/S 11.52
P/OCF 49.27
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 41.9%
ROI 35.2%
ROIC -1.1%
Profit margin 614.9%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 350.1%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -18.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 1.516B 1.618B 1.394B 767.722M 500.107M 717.045M 1.438B 21.648B 19.392B 15.04B 6.792B 898.759M 741.934M 713.74M 684.436M 569.032M
Net profit 9.323B -1.104B -995.421M 102.216M 1.816B 3.786B -286.4M 6.084B 249.998M 19.455M 421.502M 333.262M 51.911M 99.852M 42.556M 12.964M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 41.6 — — — — — — — — — — — — — — —
P/S 20.48 — — — — — — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

公告本公司研發主管異動 Bull 0 Bear 2 Management
公告本公司買回公司股份期間屆滿及執行情形 Bull 1 Bear 0 Capital return

Prompts

Center Laboratories, Inc. (ticker 4123.TWO), listed in Taiwan.

ETFs Holding Center Laboratories, Inc.

ETF Weight in ETF Shares Market value As of
AVEE 0.03% 49,731 $ 42.619K Nov 16, 2026
AVEM 0.00% 71,888 $ 61.607K Nov 16, 2026
AVSE 0.00% 2,424 $ 2,077.33 Nov 16, 2026
AVXC 0.00% 1,102 $ 944.40 Nov 16, 2026